Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status

Cancer

Volumn 121, Issue 4, 2015, Pages 545-555

  Huang, Shao Hui ^a   Waldron, John N ^a,b   Milosevic, Michael ^a   Shen, Xiaowei ^b   Ringash, Jolie ^a   Su, Jie ^b   Tong, Li ^a   Perez Ordonez, Bayardo ^b   Weinreb, Ilan ^b   Bayley, Andrew J ^a   Kim, John ^a   Hope, Andrew ^a   Cho, John ^a   Giuliani, Meredith ^a   Razak, Albiruni ^b   Goldstein, David ^b   Shi, Willa ^c   Liu, Fei Fei ^a,c   Xu, Wei ^b   O'Sullivan, Brian ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Human papillomavirus (HPV); Lymphocytes; Monocytes; Neutrophils; Oropharyngeal cancer; Outcomes

Indexed keywords

PROTEIN VP16;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER CONTROL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CIRCULATING LYMPHOCYTE COUNT; CIRCULATING MONOCYTE COUNT; CIRCULATING NEUTROPHIL COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OROPHARYNX CANCER; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; RECURRENCE FREE SURVIVAL; SMOKING; SURVIVAL PREDICTION; SURVIVAL RATE; BLOOD; COMPLICATION; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; LYMPHOCYTE; MIDDLE AGED; MONOCYTE; NEUTROPHIL; OROPHARYNX TUMOR; PREDICTIVE VALUE; PROGNOSIS; RISK; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; TONSIL TUMOR; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; ODDS RATIO; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TONGUE NEOPLASMS; TONSILLAR NEOPLASMS;

EID: 84922487903     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29100     Document Type: Article

References (52)

1. Trellakis S, Farjah H, Bruderek K, et al. Peripheral blood neutrophil granulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol. 2011;24:683-693.
2. Fernandes PC Jr, Garcia CB, Micheli DC, Cunha FQ, Murta EF, Tavares-Murta BM. Circulating neutrophils may play a role in the host response in cervical cancer. Int J Gynecol Cancer. 2007;17:1068-1074.
3. Dumitru CA, Lang S, Brandau S. Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. Semin Cancer Biol. 2013;23:141-148.
4. Tazzyman S, Niaz H, Murdoch C. Neutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growth. Semin Cancer Biol. 2013;23:149-158.
5. Bekes EM, Schweighofer B, Kupriyanova TA, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179:1455-1470.
6. Cools-Lartigue J, Spicer J, McDonald B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446-3458.
7. Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2:e22946.
8. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23:200-207.
9. Tazzyman S, Lewis CE, Murdoch C. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol. 2009;90:222-231.
10. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411-2416.
11. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol. 2011;32:317-324.
12. He JR, Shen GP, Ren ZF, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34:1769-1776.
13. Trellakis S, Bruderek K, Dumitru CA, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129:2183-2193.
14. Luo XL, He W, Huang H, et al. Design of a prognostic score model for nasopharyngeal carcinoma. Head Neck. In press.
15. Dumitru CA, Bankfalvi A, Gu X, et al. Neutrophils activate tumoral CORTACTIN to enhance progression of orohypopharynx carcinoma. Front Immunol. 2013;4:33.
16. Tsai YD, Wang CP, Chen CY, et al. Pretreatment circulating monocyte count associated with poor prognosis in patients with oral cavity cancer. Head Neck. 2014;36:947-953.
17. Wallis SP, Stafford ND, Greenman J. The clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. Head Neck. In press.
18. Dewyer NA, Wolf GT, Light E, et al. Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer. Head Neck. 2014;36:9-14.
19. Dou X, Wang RB, Yan HJ, et al. Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. Asian Pac J Cancer Prev. 2013;14:3881-3885.
20. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA. Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J. 2007;86:506-511.
21. Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110:489-500.
22. Andersen AS, Koldjaer Solling AS, Ovesen T, Rusan M. The interplay between HPV and host immunity in head and neck squamous cell carcinoma. Int J Cancer. 2014;134:2755-2763.
23. O'Sullivan B, Huang SH, Perez-Ordonez B, et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol. 2012;103:49-56.
24. Huang SH, Perez-Ordonez B, Weinreb I, et al. Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. 2013;49:79-89.
25. O'Sullivan B, Huang SH, Siu LL, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31:543-550.
26. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27:6213-6221.
27. Wong K, Huang SH, O'Sullivan B, et al. Point-of-care outcome assessment in the cancer clinic: audit of data quality. Radiother Oncol. 2010;95:339-343.
28. Edge S, Byrd D, Compton C. Pharynx. AJCC Cancer Staging Manual. New York: Springer, 2010:41-56.
29. Sobin L, Gospodarowicz M, Wittekind C. Pharynx. 7th ed. New York, NY: Wiley-Blackwell; 2010:30-38.
30. ClinicalTrials.gov. Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial). http://clinicaltrials.gov/ct2/show/NCT00147472. Accessed March 30, 2011.
31. NCIC Clinical Trials Group (NCIC CTG). Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer (HN6) [NCT00820248]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00820248?term5NCT00820248&rank=1. Accessed on July 5, 2014.
32. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. J Clin Oncol. 2014. (in press).
33. Huang SH, O'Sullivan B, Xu W, et al. Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys. 2013;87:1078-1085.
34. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
35. Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26:1360-1367.
36. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
37. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
38. King EV, Ottensmeier CH, Thomas GJ. The immune response in HPV oropharyngeal cancer. Oncoimmunology. 2014;3:e27254.
39. Al-Zubaydi ZH. White blood cells (WBCs) or leukocytes. http://repository.uobabylon.edu.iq/2010-2011/4-25882-626.pdf. Accessed August 1, 2014.
40. DeNardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 2010;29:309-316.
41. Carus A, Ladekarl M, Hager H, Nedergaard BS, Donskov F. Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. Br J Cancer. 2013;108:2116-2122.
42. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010;70:5679-5685.
43. Ahn GO, Brown JM. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle. 2009;8:970-976.
44. Ng WL, Huang Q, Liu X, Zimmerman M, Li F, Li CY. Molecular mechanisms involved in tumor repopulation after radiotherapy. Transl Cancer Res. 2013;2:442-448.
45. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A. 2010;107:8363-8368.
46. Overbeek SA, Braber S, Koelink PJ, et al. Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One. 2013;8:e55612.
47. Hao S, Andersen M, Yu H. Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients. Am J Blood Res. 2013;3:239-245.
48. Choi J, Suh B, Ahn YO, et al. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol. 2012;33:121-129.
49. Brooks N, Stojanovska L, Grant P, Apostolopoulos V, McDonald CF, Pouniotis DS. Characterization of blood monocyte phenotype in patients with endometrial cancer. Int J Gynecol Cancer. 2012;22:1500-1508.
50. Balermpas P, Michel Y, Wagenblast J, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110:501-509.
51. Nasman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One. 2012;7:e38711.
52. Wansom D, Light E, Thomas D, et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope. 2012;122:121-127.